Background. The use of anthracyclines in metastatic breast cancer (MBC) is limited by cumulative dose-dependent cardiotoxicity mostly in elderly women with comorbidities. The aim of this observational retrospective study was to evaluate the efficacy of non-pegylated liposomal doxorubicin (Myocet®) and cyclophosphamide in elderly women as HER2 negative first-line MBC treatment. Methods. 84 elderly women >70 years of age (median age 78 years) with MBC HER2 negative were enrolled. Performance Status in 58 patients was ECOG-0 and in 26 patients was ECOG-1. Results. The drug was well tolerated, with overall response rates were >40%, median overall survival was 16.2 months (95%CI:14.6- 18.8) and median progression free survival was 5.8 months (95%CI:4.4- 8.6). Hematologic toxicity with neutropenia was the most frequent adverse event , but the treatment was well tolerated maintained a manageable cardiotoxicity. Conclusion. Non-pegylated liposomal doxorubicin may represent a valid therapeutic option in first-line for elderly patients with HER/2 negative MBC improving survival, anti-tumor response rate and decreases cardiotoxicity

S.I.S. Fattoruso, R.D.L. (2021). Non-pegylated liposomal doxorubicin plus cyclophosphamide as first-line therapy in elderly women with HER2 negative metastatic breast cancer. LA CLINICA TERAPEUTICA, 173(2), 121-127 [10.7417/CT.2022.2405].

Non-pegylated liposomal doxorubicin plus cyclophosphamide as first-line therapy in elderly women with HER2 negative metastatic breast cancer

G. Cicero
Ultimo
2021-01-01

Abstract

Background. The use of anthracyclines in metastatic breast cancer (MBC) is limited by cumulative dose-dependent cardiotoxicity mostly in elderly women with comorbidities. The aim of this observational retrospective study was to evaluate the efficacy of non-pegylated liposomal doxorubicin (Myocet®) and cyclophosphamide in elderly women as HER2 negative first-line MBC treatment. Methods. 84 elderly women >70 years of age (median age 78 years) with MBC HER2 negative were enrolled. Performance Status in 58 patients was ECOG-0 and in 26 patients was ECOG-1. Results. The drug was well tolerated, with overall response rates were >40%, median overall survival was 16.2 months (95%CI:14.6- 18.8) and median progression free survival was 5.8 months (95%CI:4.4- 8.6). Hematologic toxicity with neutropenia was the most frequent adverse event , but the treatment was well tolerated maintained a manageable cardiotoxicity. Conclusion. Non-pegylated liposomal doxorubicin may represent a valid therapeutic option in first-line for elderly patients with HER/2 negative MBC improving survival, anti-tumor response rate and decreases cardiotoxicity
2021
S.I.S. Fattoruso, R.D.L. (2021). Non-pegylated liposomal doxorubicin plus cyclophosphamide as first-line therapy in elderly women with HER2 negative metastatic breast cancer. LA CLINICA TERAPEUTICA, 173(2), 121-127 [10.7417/CT.2022.2405].
File in questo prodotto:
File Dimensione Formato  
myocet 2022.pdf

Solo gestori archvio

Tipologia: Versione Editoriale
Dimensione 187.42 kB
Formato Adobe PDF
187.42 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/569371
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? ND
social impact